Six1 is a critical regulator of embryonic development that requires interaction with the Eya family of proteins (Eya1-4) to activate the transcription of genes involved in neurogenesis, myogenesis and nephrogenesis. Although expression of Six1 and Eya family members is predominantly observed in development, their overexpression is observed in numerous cancers. Importantly, both Six1 and Eya have independently been shown to mediate breast cancer metastasis, but whether they functionally interact during tumor progression has not been explored. Herein, we demonstrate that knockdown of Eya2 in MCF7 mammary carcinoma cells reverses the ability of Six1 to induce transforming growth factor-b signaling, as well as to induce characteristics associated with epithelial-mesenchymal transition and cancer stem cells, suggesting that Six1 is dependent on Eya2 to mediate numerous prometastatic characteristics. The importance of the Six1-Eya interaction in human breast cancer is underscored by the finding that high levels of Six1 correlate with shortened time to relapse and metastasis as well as decreased survival only when co-expressed with high levels of Eya2. Overall, these data implicate Eya2 as a necessary co-factor for many of the metastasis promoting functions of Six1, suggesting that targeting the Six1-Eya interaction may inhibit breast cancer progression. As Six1 and Eya2 are not highly expressed in most adult tissues, the Six1-Eya interaction may be a valuable future therapeutic target whose inhibition would be expected to impair breast cancer progression while conferring limited side effects.
Introduction
Many processes necessary for early embryonic development are recapitulated in cancer, often as a result of homeobox gene re-expression (Ford, 1998; Cillo et al., 1999; Samuel and Naora, 2005) . Such inappropriate expression of homeobox genes, which encode transcription factors, allows for the acquisition of early developmental phenotypes, such as proliferation, survival, invasion and migration in adult cells, thereby contributing to tumorigenesis and/or tumor progression (Abate-Shen, 2002) . The Six1 homeobox gene has a critical role in the development of a number of organs via promoting proliferation, survival, migration and invasion of precursor cell populations (Li et al., 2003; Xu et al., 2003; Laclef et al., 2003a, b) . In muscle development, Six1 contributes to the delamination and migration of myogenic precursor cells from the dermomyotome to the developing limb, in a process that entails an epithelial-mesenchymal transition (EMT) (Xu et al., 2003; Laclef et al., 2003a, b) . In addition to the role of Six1 in development, recent work has identified misexpression of Six1 in numerous cancers including breast Reichenberger et al., 2005) , ovarian (Behbakht et al., 2007) , cervical (Zheng et al., 2010) , hepatocellular carcinoma (Ng et al., 2006) , as well as Wilms' tumors (Li et al., 2002) and alveolar rhabdomyosarcomas (Yu et al., 2004) . Importantly, Six1 overexpression in cancer recapitulates the pro-proliferative, pro-survival and pro-migratory phenotypes attributed to Six1 in development (Coletta et al., 2004; Yu et al., 2004; Behbakht et al., 2007; Micalizzi et al., 2009) .
Six1 belongs to the evolutionarily conserved Six1-Eya-Dach transcriptional regulatory network that is critical during embryonic development. Members of the Eya family of Six1 co-activators (Eya1-4) have critical roles in Six1-mediated transcriptional activation. Six1 and Eya1 knockout mice phenocopy each other, and both molecules are necessary for the proper development of ears, muscle, kidney, thymus and sensory neurons, as well as for overall neonatal survival (Xu et al., 2002 (Xu et al., , 2003 Li et al., 2003; Laclef et al., 2003b; Ando et al., 2005) . The phenotypes observed in both KO mice are, at least in-part, because of poor progenitor cell proliferation and survival, underscoring the role of the Six1-Eya complex in the expansion of progenitor cell populations during normal development. The role of the Six1-Eya complex in human disease is also clear, as both Six1 and Eya1 mutations can be found in branchio-oto-renal syndrome, where mutations disrupt individual protein function, Six1-DNA binding, and Six1-Eya1 binding (Vincent et al., 1997; Abdelhak et al., 1997a, b; Ruf et al., 2004; Kochhar et al., 2008; Orten et al., 2008; Patrick et al., 2009) . Additionally, Eya4 mutations are observed in sensorineural hearing loss (Wayne et al., 2001; Zhang et al., 2004; Schonberger et al., 2005) where Eya4 function and Six1-Eya4 interactions are lost. Together, data from both mouse models and human disease underscore the critical developmental function of the Six1-Eya interaction.
Although not highly expressed in most adult tissues, Six1 is misexpressed in multiple cancers and re-instates a pro-proliferative and pro-survival phenotype (Coletta et al., 2004; Yu et al., 2006) . In breast cancer, Six1 also induces EMT-and stem cell-like phenotypes (McCoy et al., 2009) , the former of which is mediated through upregulating transforming growth factor (TGF)-b signaling (Micalizzi et al., 2009) and is likely critical for Six1-induced metastasis. Six1 correlates with advanced disease in many types of cancer, including breast (Micalizzi et al., 2009) , ovarian (Behbakht et al., 2007) and alveolar rhabdomyosarcomas (Yu et al., 2004) . Overexpression of Eya1 and Eya2 family members have been identified in many of the same cancers as Six1 (Li et al., 2002; Zhang et al., 2005) . In ovarian cancer, two independent studies have demonstrated that Six1 and Eya2 each correlate with poor patient survival in advanced disease Behbakht et al., 2007) ; however, as of yet, the role of Six1 and Eya together in cancer has not been studied. Importantly, Eya was recently shown to increase proliferation, migration, invasion, transformation and metastasis in mammary carcinoma cells (Pandey et al., 2010) ; suggesting that Eyas, like Six1, have an important role in breast cancer and that they may in fact cooperate with Six1 to confer pro-proliferative and migratory phenotypes. Although a non-nuclear function of Eya was postulated to mediate its pro-tumorigenic phenotypes (Pandey et al., 2010) , no formal experiments were conducted to test the relevance of the interaction between Six1 and Eya in breast tumorigenesis and/or metastasis.
In this study, we demonstrate a cooperative role between Six1 and Eya in mediating phenotypes associated with breast tumorigenesis and metastasis. Knockdown of Eya2 in Six1 overexpressing MCF7 mammary carcinoma cells reverses Six1-mediated induction of TGF-b signaling, as well as the ability of Six1 to induce EMT and an increase in cancer stem cell (CSC) characteristics. The relevance of the Six1-Eya interaction in human breast cancer is underscored in gene expression data sets, where only co-expression of Six1 and Eya can predict poor patient prognosis. Taken together, these data strongly support the hypothesis that Eya is a critical activator of Six1 in human breast cancer, where it is required to mediate Six1-induced TGF-b-dependent EMT and expansion of the cancer stem-like cell population.
Results

Eya2 is the predominant Eya in MCF7 cells
We have previously shown that Six1 overexpression in the MCF7 mammary carcinoma cell line activates the TGF-b pathway (Micalizzi et al., 2009 ), leading to a loss of epithelial and gain of mesenchymal characteristics.
To determine whether Six1 requires the Eya family of co-factors to mediate these phenotypes, we first examined which Eyas, if any, are expressed in MCF7 cells. Using quantitative reverse transcriptase-PCR with plasmid standard curves and primers that specifically recognize individual Eya members, we determined the mRNA copy number of each Eya in MCF7 cells overexpressing Six1 (MCF7-Six1) and control (MCF7-Ctrl). Importantly, we identified Eya2 as the predominant Eya family member in MCF7 cells, exhibiting fivefold greater expression than Eya3. In contrast, Eyas 1 and 4 were absent or expressed only at very low levels ( Figure 1a ). To determine the dependence of Six1 phenotypes on Eya2 function, we stably and specifically knocked down Eya2 in MCF7-Six1 cells using two independent short hairpin RNA (shRNA) sequences. Independent control cell lines were also established in which a scramble shRNA control was introduced into MCF7-Six1 and MCF7-Ctrl cells. Two clonal isolates were propagated from each shRNA in each line to control for insertion site effects. Eya2 mRNA and protein levels were determined in each clone (Figures 1b and c) , and on average, we achieved a 75% knockdown.
Eya2 knockdown in MCF7-Six1 cells reverses the ability of Six1 to induce TGF-b signaling
We have previously shown that Six1 activates the TGFb signaling pathway when overexpressed in MCF7 cells (Micalizzi et al., 2009 (Micalizzi et al., , 2010 . Using our Eya2 knockdown cells, we examined the dependence of Six1 on Eya2 in mediating increased TGF-b signaling. As we have observed that Six1 overexpression leads to an increase both in the levels of the type I TGF-b receptor (Micalizzi et al., 2010) and in total Smad3 levels (Micalizzi et al., 2009) , each which may contribute to the overall increase in TGF-b signaling, we first examined whether loss of Eya2 would reverse the Six1mediated increases in these protein levels. Indeed, Eya2 knockdown reverses the Six1-mediated increase in the levels of type I TGF-b receptor and Smad3 (Figure 2b ). Further, Eya2 knockdown in MCF7 cells leads to decreased signaling downstream of TGF-b as measured by 3TP-luciferase activity, a measurement of Smadmediated TGF-b-responsive transcription (Figure 2c ). Finally, co-expression of Six1 and Eya2 increases both total and p-Smad3 levels in NMuMG cells above that observed with expression of Six1 or Eya2 alone, suggesting that the two proteins cooperate to activate TGF-b signaling in multiple contexts (Supplementary Figure 1 ). Together, these data demonstrate that Eya2 is necessary for the ability of Six1 to activate TGF-b signaling.
Eya2 knockdown partially reverses the ability of Six1 to induce EMT In both cell culture and animal models, Six1 overexpression results in the loss of the epithelial phenotype with a concomitant gain in the mesenchymal phenotype (McCoy et al., 2009; Micalizzi et al., 2009) . We have previously shown that this EMT requires Six1-induced TGF-b signaling (Micalizzi et al., 2009) , and thus asked whether Six1 is also dependent on Eya2 to mediate EMT. In support of the hypothesis that Six1 requires Eya2 to mediate an EMT, knockdown of Eya2 in MCF7-Six1 cells reverses the Six1-induced increase in the mesenchymal marker fibronectin (Figure 3a ). Additionally, Eya2 is required for the Six1-induced relocalization of E-cadherin and b-catenin away from the insoluble (membranous) fraction and into the soluble (cytoplasmic/nuclear) fraction, a hallmark of EMT (Figures 3b and c) . As expected, the decreased levels of soluble b-catenin in the presence of Eya2 knockdown correlates with decreased Six1-induced b-catenin-responsive transcription as measured by TOP-FLASH reporter activity ( Figure 3d ). These data demonstrate that Eya2 is required for the ability of Six1 to induce and/or maintain features of EMT associated with the induction of mesenchymal properties. However, loss of Eya2 did not restore cytokeratin 18 expression to MCF7 cells, which is normally downregulated in the presence of Six1 (data not shown), nor did it reverse the decrease in cell-matrix adhesion observed with Six1 overexpression ( Figure 3e ). This suggests that either: (1) Eya2 is not globally required for Six1-induced EMT, or (2) that some Six1-induced characteristics of EMT are permanent once induced and no longer dependent on Six1 function.
Six1 is dependent on Eya2 for enhancement of cancer stem/progenitor cell characteristics
We recently demonstrated that Six1 promotes a stem/ progenitor cell phenotype when overexpressed in mouse mammary glands and that tumors, which arise in these transgenic mice appear to be derived from a stem/progenitor cell population ( Thus, we set out to test whether Eya2, which is required for the ability of Six1 to induce TGF-b signaling and EMT, is also required for the ability of Six1 to induce a CSC-like phenotype. Although Six1 overexpression of MCF7 cells leads to an increase in the population of cells that are CD44 þ and CD24À, markers of mammary stem/progenitor cells (Al-Hajj et al., 2003) , loss of Eya2 significantly reverses this increase (Figure 4a and Supplementary Figure 2 ). Furthermore, knockdown of Eya2 reverses the increase in functional cancer stem-like cells observed with Six1 overexpression, as demonstrated in secondary tumorsphere formation assays ( Figure 4b ). Interestingly, Six1 overexpression not only increases the number of tumorspheres formed by MCF7 cells, but it significantly alters their morphology from a uniformed sphere to a less organized shape, a phenotype that is also reversed with Eya2 knockdown (Figure 4c ). Together, these results show that Eya2 is necessary for the ability of Six1 to induce characteristics of cancer stem/progenitor-like cells.
Co-expression of Eya2 and Six1 correlates with activated TGF-b signaling in human breast cancer We previously demonstrated that Six1 induces metastasis via increasing TGF-b signaling. Additionally, we have shown that high levels of Six1 correlate with high levels of activated TGF-b signaling as well as with adverse outcomes in human breast cancer (Micalizzi et al., 2009 ). On the basis of our results suggesting that Eya2 is required for Six1-activated TGF-b signaling, we performed immunohistochemical analysis on breast cancer tissue arrays to determine if Six1 is dependent on Eya2 to mediate TGF-b signaling in human breast cancer. We first produced and characterized an Eya2specific antibody using an N-terminal Eya2 peptide. Importantly, this newly developed antibody specifically recognizes Eya2 as opposed to other Eya family members ( Supplementary Figure 3 ). Using tissue arrays containing 50 malignant primary breast tissue samples, immunohistochemical analysis was performed with antibodies against Eya2, Six1 and Smad3, which when nuclear is an indicator of active TGF-b signaling. Following blinded scoring, the data were divided into above the mean and below the mean nuclear staining for Six1 and Eya2. Co-expression of high levels of Six1 and Eya2 significantly correlates with nuclear localized Smad3 ( Figure 5 ), supporting a critical cooperative role for Six1 and Eya in mediating TGF-b signaling in human breast cancer. Eya2 is required for Six1-induced tumor progression SM Farabaugh et al survival ( Supplementary Figure 4) . However, in breast cancer patients whose tumors expressed high Six1 levels in the absence of high Eya2, as well as high Eya2 levels in the absence of high Six1, there is NO correlation with any of these parameters. In contrast, only when tumors express BOTH high levels of Six1 and Eya2 together, is a strong significant correlation found with shortened time to relapse, shortened time to metastasis and with shortened survival (Figure 6 ). These results can be corroborated in the independent Wang data set , consisting of 286 lymph-node-negative breast cancer patients (Supplementary Figure 5) . These data strongly suggest that Six1 and Eya2 cooperate in human breast cancer and reinforce the hypothesis that Eya2 is required for the ability of Six1 to mediate tumor progression. As Eya1, Eya2 and Eya4 have all been implicated in cancer, we extended our analysis of the van de Vijver data set to examine whether any Eya family member is able to cooperate with Six1 in human breast cancer, or whether this cooperation is specific to Eya2. Importantly, in the van de Vijver data set, Eya1 in conjunction with Six1 also significantly associates with shortened time to relapse and to metastasis, as well as with shortened survival (Figure 7) , and although not significant, Eya1 does show a cooperative trend with Figure 6) . In comparison, Eya3 only correlates with survival in the van de Vijver data set and Eya4 does not correlate with any adverse outcome in conjunction with Six1 in either data set (data not shown). Together, these data strongly suggest that Eya1 and Eya2 are both able to cooperate with Six1 in human breast cancer.
Discussion
The Six homeobox transcription factor reactivates developmental pathways out of context in numerous tumor types, likely contributing to both tumor initiation and tumor progression. Downstream pathways involved in, and required for, Six1-activated tumor initiation and Eya2 is required for Six1-induced tumor progression SM Farabaugh et al tumor progression have been studied intensely over the past few years (Coletta et al., 2004; Yu et al., 2006; Micalizzi et al., 2009 Micalizzi et al., , 2010 . As Six1 has no intrinsic activation or repression domains, we hypothesized that it would require a co-factor(s) to mediate its tumor promotional characteristics. As members of the developmentally required Eya co-activator family are overexpressed in many of the same cancers as Six1, including ovarian cancer where both Six1 and Eya2 correlate with advanced-disease and poor patient survival Behbakht et al., 2007) , we pursued Eya proteins as relevant required co-factors of Six1 in human breast cancer. To establish if Six1 requires Eya to mediate its tumorigenic effects, we knocked down Eya2 in MCF7 mammary carcinoma cells overexpressing Six1. In this study, we demonstrate for the first time, a cooperative role for Six1 and Eya in mediating the pro-metastatic phenotypes induced by Six1. Eya2 is required by Six1 to activate TGF-b signaling, as well as to induce both EMT and CSC-like characteristics. These data are supported clinically by the demonstration that Six1 and Eya2 are co-expressed with activated TGF-b signaling, and that the two proteins together, but not individually, correlate with shortened time to relapse and metastasis and with decreased survival. These results strongly suggest that Eya2 and Six1 act in concert to promote breast tumor progression.
Although all Eya family members cooperate with Six1 to mediate Six1-induced transcription in cell culture models (Ohto et al., 1999; Li et al., 2003; Zhang et al., 2004) , we demonstrate that only Eya1 and Eya2 strongly collaborate with Six1 in human breast cancer. This association of Six1 with Eya1 and Eya2 is not surprising as Eya1 and Six1 knockout mice phenocopy each other (Xu et al., 1999 (Xu et al., , 2003 Li et al., 2003; Laclef et al., 2003b; Ando et al., 2005) and as Eya2 and Six1 both correlate with advanced disease and decreased survival in ovarian cancer Behbakht et al., 2007) . In contrast, overexpression of Eya3 has not been observed in cancer, nor has an endogenous role for Eya3 with Six1 been demonstrated. Interestingly, Eya4 is methylated and downregulated in gastrointestinal cancers (Zou et al., 2005; Osborn et al., 2006) , but is overexpressed in malignant peripheral nerve sheath tumors along with other Eya and Six family members (Miller et al., 2010) , suggesting that Eya4 may have roles in both tumor suppression and progression, depending on the context. Thus, while Eya1 and Eya2 appear to be the key Eya family members necessary for Six1mediated tumor progression in the breast, we hypothesize that, given the correct context, any Eya family Figure 6 Coordinate high Six1 and Eya2 expression are required to predict poor prognosis in human breast cancer. In a gene expression data set of 295 women with early-stage invasive breast carcinoma (van 't Veer et al., 2002) , patient samples expressing high Six1 in the absence of high Eya2, and high Eya2 in the absence of high Six1, do not correlate with reduced time to metastasis, reduced time to relapse and shortened breast cancer-specific survival while high Six1 and high Eya2 together in the same patient sample significantly correlates with shortened time to relapse and to metastasis, and with shortened breast cancer-specific survival. The mean value for Six1 and/or Eya2 expression was used to divide the samples into high (above the mean) and low (below the mean) Six1 and Eya2 expression. P-values were calculated by log-rank analysis.
Eya2 is required for Six1-induced tumor progression SM Farabaugh et al member may be sufficient to cooperate with Six1 to mediate tumorigenesis. Interestingly, a recent study demonstrates that overexpression of Eya in MCF7 mammary carcinoma cells promotes proliferation, transformation, migration and invasion of breast cancer cells, while knockdown of Eya3 in MDA-231 metastatic mammary carcinoma cells inhibits invasion, migration and metastasis in nude mice (Pandey et al., 2010) . The investigators of this recent study suggest that Eya promotes tumorigenic phenotypes largely through cytoplasmic functions, because nuclear targeted Eya did not induce transformation, migration or invasion of breast cancer cells to the same extent as wild-type Eya protein. Although a cytoplasmic function for Eya likely contributes to its ability to mediate tumorigenic and metastatic phenotypes, the cell lines used in this study contain low levels of Six1, making it difficult to assess the dependence of Eya on Six1 in this context. It has previously been shown that the presence of Six family members significantly affects the percentage of Eya proteins located in the nucleus versus the cytoplasm (Ohto et al., 1999) , and that the cytoplasmic/nuclear Eya ratio is further influenced by expression of Abl and G-alpha i proteins, which function with Eya in the cytoplasm (Fan et al., 2000; Embry et al., 2004; Xiong et al., 2009) . Interestingly, complete eye restoration in Drosophila requires balanced nuclear and cytoplasmic eya expression (Xiong et al., 2009 ), suggesting that full Eya function may require spatial regulation between the two Eya pools. Indeed, while the cytoplasmic function of non-targeted Eya was deemed critical for the pro-tumorigenic and metastatic properties observed in the aforementioned study, nuclear targeted Eya still increased pro-tumorigenic/metastatic phenotypes threefold above baseline (Pandey et al., 2010) , suggesting that the cytoplasmic and nuclear functions of Eya may cooperate to impart the tumorigenic response. Importantly, the requirement of a direct Six1-Eya interaction in mediating metastatic phenotypes, as opposed to the two proteins working in parallel cooperative pathways, is not yet known. Nonetheless, the cell culture models used in this study are strongly supported by the clinical data published herein, and indicate that Six1 and Eya indeed require each other to mediate breast cancer progression.
In addition to its transactivation activity, Eya contains two phosphatase activities, N-terminal serine/ threonine phosphatase activity and C-terminal tyrosine phosphatase activity. The C-terminal tyrosine phosphatase activity acts in the nucleus to activate a repair and survival pathway by dephosphorylating H2AX in response to DNA damage (Cook et al., 2009; Krishnan et al., 2009) and in the cytoplasm to mediate phosphotyrosine signaling networks during Drosophila development by interacting with the Abelson tyrosine kinase (abl) (Xiong et al., 2009) . The N-terminal serine/ threonine phosphatase activity has a role in the cytoplasm, where it is required for the ability of Eya4 Figure 7 Coordinate high Six1 and Eya1 expression are required to predict poor prognosis in human breast cancer. In a gene expression data set of 295 women with early-stage invasive breast carcinoma (van 't Veer et al., 2002) , patient samples expressing high Six1 in the absence of high Eya1, and high Eya1 in the absence of high Six1, do NOT correlate with reduced time to metastasis, time to relapse and shortened breast cancer-specific survival while high Six1 and high Eya1 together in the same patient sample significantly correlates with the aforementioned prognostic indicators. The mean value for Six1 and/or Eya1 expression was used to divide the samples into high (above the mean) and low (below the mean) Six1 and Eya1 expression. P-values were calculated by log-rank analysis.
Eya2 is required for Six1-induced tumor progression SM Farabaugh et al to enhance the innate immune response (Okabe et al., 2009) . Significantly, the tyrosine phosphatase activity of Eya is necessary for Eya-induced migration, invasion, transformation and metastasis (Pandey et al., 2010) . The requirement for Eya phosphatase activity in mediating transcriptional activation, specifically through Six1, has not been completely elucidated, particularly in mammalian cells. Early in vitro studies analyzing activation of Six1 reporter promoters suggest that the Eya phosphatase activity is important to co-activate transcription through Six1 (Li et al., 2003) . However, a more recent study in Drosophila suggests Eya phosphatase activity is only required for a subset of Six1 transcriptional targets (Jemc and Rebay, 2007) . Thus, the role of Eya phosphatase activity in mediating Six1-induced prometastatic phenotypes remains to be determined.
In conclusion, we have found that the Eya coactivator is required for the ability of Six1 to mediate a number of pro-metastatic properties, and that the two molecules together significantly predict adverse outcomes in human breast cancer. Understanding the necessity of Six1 on both a direct interaction with Eya and on the Eya phosphatase activity is important for future development of anticancer agents that target the Six1-Eya complex. Six1 and Eya2 are implicated in advanced breast cancer and are not normally expressed in most adult tissues. Thus, inhibiting these proteins in breast, ovarian and other carcinomas may result in a therapeutic agent that would target tumor progression with limited side effects to patients.
Materials and methods
Cell culture
One MCF7-Six1 and one MCF7-Ctrl stable clone was stably transfected using Effectene (Qiagen, Valencia, CA, USA) with five shRNA constructs and one scramble negative control in the SureSilencing pGeneClip vector (SABiosciences, Frederick, MD, USA). Cells were selected with 2.5 mg/ml puromycin and two individual clonal isolates chosen from each of two working Eya2 shRNA constructs (shRNA1: 5 0 -CGTGCGCATTGGCCTTATGAT-3 0 ; shRNA2: 5 0 -GGGTTCTATCAAGGAGGAAAT-3 0 ), as well as two scrambled control clones (5 0 -GGAATCTCATTCGATGCA TAC-3 0 ).
Real-time PCR
Total RNA was TRIzol isolated and RNeasy mini kit purified (Qiagen). Quantification to compare Eya mRNA levels was performed using plasmid standard curves and calculation of copy number for each Eya mRNA. Relative expression was used for comparison of Eya2 levels between shRNA clones and determined by DDCT method (Livak and Schmittgen, 2001) . Supplementary Figure 7 lists primer and probes.
Antibody production
An Eya2 antibody was produced by Proteintech Group, Inc. (Chicago, IL, USA). An N-terminal Eya2 peptide (aa17-37: LDKLKFNRADAAVWTLSDRQG) was KLH, keyhole limpet hemocyanin, conjugated. In all, 1 mg of peptide was injected on day 1 with boosts on days 28, 40, 58 and 76 and bleeds on days 72 and 102. The antibody was antigen affinity purified and tested on lysates from MCF7 cells transfected with Eya2 or Eyas 1, 3, 4 for control.
Immunofluorescence
Cells were grown on glass slides, fixed with formaldehyde, permeablized with 0.5% Triton X-100/phosphate-buffered saline, incubated with Eya2 antibody (1:100), then with Texas Red-conjugated anti-rabbit immunoglobulin G antibody (Sigma-Aldrich, St Louis, MO, USA) and stained with 4,6-diamidino-2-phenylindole.
Western blot analysis
Western blot analysis was performed on whole cell lysates made with RIPA buffer (Ford et al., 2000) . Primary antibodies used were: E-cadherin, b-catenin, and Fibronectin (BD Biosciences, San Diego, CA, USA), b-actin (Sigma-Aldrich), Smad3 (Invitrogen, Carlsbad, CA, USA) Eyas 1, 3, 4 (SantaCruz Biotechnology, Santa Cruz, CA, USA). Cell fractionation performed as previously described (Shtutman et al., 2006) .
3TP and TOP-flash luciferase
Eya2 and scramble shRNA clones were plated in triplicate at 110 000 cells per well in a 12-well plate. After 24 h, cells were co-transfected with 3TP (Wrana et al., 1992) or pTOP-flash plasmid (Korinek et al., 1997) , and a renilla luciferase construct containing a cryptic promoter, using FuGENE 6 (Roche, Indianapolis, IN, USA). After 48 h, lysates were prepared and analyzed with the Dual Luciferase Kit (Promega, Madison, WI, USA) on a Modulus Microplate (Turner Biosystems, Sunnyvale, CA, USA).
Cell adhesion
For cell adhesion, 96-well plates coated with laminin, fibronectin, collagen I or collagen IV (BD Biosciences, Biocoat) were blocked with 1% bovine serum albumin for 1 h. In all, 2.5 Â 10 4 cells were added, incubated 1 h at 37 1C, and then washed three times with phosphate-buffered saline, fixed for 10 min with cold methanol, stained with 0.04% crystal violet and solubilized with 10% glacial acetic acid. Absorbance was determined at 570 nm on a microplate reader (Molecular Devices, Sunnyvalle, CA, USA).
CSC assays
In all, 7.5 Â 10 5 cells were plated and grown for 48 h. For flow cytometry analysis, cells were trypsinized, washed with 0.5% bovine serum albumin-phosphate-buffered saline, stained with anti-CD44-APC and anti-CD24-biotin (BD Biosciences) (1:100) for 30 min, then stained with anti-streptavidin-V450 (BD Biosciences) (1:1000) for 30 min, and resuspended in 400 ml of 0.06 mg/ml PI with 0.5% bovine serum albuminphosphate-buffered saline. Fluorescence was detected with CyAn (Beckman Coulter, Brea, CA, USA). For tumorsphere assays, cells were trypsinized and re-plated at 1000 cells/ml in six-well, ultra-low attachment plates (Thermo Fisher-Scientific, Waltham, MA, USA) in 2 ml of serum-free Dulbecco's modified Eagle's medium/F12 media (Hyclone,Thermo Fisher Scientific), supplemented with 20 ng/ml bFGF (basic fibroblast growth factor) (BD Biosciences), 20 ng/ml EGF (epidermal growth factor) (BD Biosciences), 4 mg/ml heparin (Sigma), penicillin-streptomycin (Hyclone, Thermo Fisher Scientific) and B27 (Gibco, Invitrogen). The cells were fed 1 ml of media every 2-3 days. On day 10, all cells and spheres were collected, digested using 0.05% trypsin with 0.53 mm EDTA-4Na (Invitrogen), and single cells plated as above at 2000 cells per well to perform secondary assays. Tumorspheres were counted on day 8 of second passage.
Immunohistochemistry
Tumor array BRC711 was obtained from US Biomax (Rockville, MD, USA). Paraffin-embedded sections were stained as previously described (Harrell et al., 2006) following the ImmPRESS kit protocol (Vector Laboratories, Burlingame, CA, USA). Primary antibodies included Eya2 (1:300), Six1 (1:75; Atlas Antibodies, Stockholm, Sweden) and Smad3 (5 mg/ ml; Invitrogen). Nuclear staining intensity in tumor cells was scored in a blinded fashion by a pathologist (PJ) on a 0-4 scale with 4 corresponding to most intense staining.
Analysis of microarray data
Gene expression and clinical outcome data were obtained from the van de Vijver and Wang data sets (van 't Veer et al., 2002; Wang et al., 2005) . Six1 and Eya1-4 gene expression was obtained for each tumor sample. All samples were meancentered for each gene and divided into two groups: samples that express the denoted gene or gene combination above (high) or below the mean (low) and the rest of the samples that did not fit the denoted gene expressions (other). Each data set was analyzed separately. Kaplan-Meier survival curves were generated using WinStat for Excel (R Fitch Software, A-Prompt Corp, Whitehall, PA, USA). Normalization was obtained from the Stanford Microarray Database (van de Vijver) and NCBI GEO (Wang: GSE2034).
